Product Code: ETC4538009 | Publication Date: Jul 2023 | Updated Date: Aug 2025 | Product Type: Report | |
Publisher: 6Wresearch | No. of Pages: 85 | No. of Figures: 45 | No. of Tables: 25 | |
The HMO market in Indonesia is an emerging sector, reflecting a growing interest in infant nutrition and early childhood development. HMOs, known for their beneficial effects on infant gut health and immune system development, are gaining traction among both consumers and manufacturers of infant formula. This market is expected to see substantial growth in the coming years as awareness about the importance of early childhood nutrition increases.
Growing recognition of the health benefits associated with breast milk components, particularly human milk oligosaccharides, has been a significant driver in the HMO market in Indonesia. Research highlighting the role of HMOs in supporting infant immune systems and gut health has led to a surge in demand for products containing these bioactive compounds. This trend is further supported by a rising emphasis on infant nutrition and maternal health.
The Indonesia HMO market encounters challenges associated with the limited awareness and acceptance of HMOs in infant nutrition. Consumer education and regulatory compliance are critical hurdles. Moreover, sourcing and producing HMOs in a cost-effective and sustainable manner may be a complex task.
The HMO market in Indonesia faced challenges due to COVID-19. Infant formula and related products experienced some supply chain disruptions, impacting the availability of HMO ingredients. Additionally, economic uncertainties affected consumer purchasing power. However, the awareness of the importance of HMOs in infant nutrition continued to drive demand, resulting in a relatively stable market.
Key players in the Indonesia HMO market include Jennewein Biotechnologie GmbH, Glycosyn LLC, and Inbiose NV.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Indonesia Human Milk Oligosaccharides (HMO) Market Overview |
3.1 Indonesia Country Macro Economic Indicators |
3.2 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, 2021 & 2031F |
3.3 Indonesia Human Milk Oligosaccharides (HMO) Market - Industry Life Cycle |
3.4 Indonesia Human Milk Oligosaccharides (HMO) Market - Porter's Five Forces |
3.5 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.7 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume Share, By Concentration, 2021 & 2031F |
4 Indonesia Human Milk Oligosaccharides (HMO) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about the health benefits of human milk oligosaccharides (HMOs) in Indonesia |
4.2.2 Growing demand for infant formula with added HMOs due to rising disposable income levels |
4.2.3 Technological advancements in the production and extraction of HMOs |
4.3 Market Restraints |
4.3.1 High production costs associated with extracting and incorporating HMOs into infant formula |
4.3.2 Limited availability of HMO-enriched products in the market, leading to supply chain constraints |
5 Indonesia Human Milk Oligosaccharides (HMO) Market Trends |
6 Indonesia Human Milk Oligosaccharides (HMO) Market, By Types |
6.1 Indonesia Human Milk Oligosaccharides (HMO) Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, By Type, 2021-2031F |
6.1.3 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, By 2?? Fl, 2021-2031F |
6.1.4 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, By 3?? Fl, 2021-2031F |
6.1.5 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, By 3?? Sl, 2021-2031F |
6.1.6 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, By 6?? Sl, 2021-2031F |
6.2 Indonesia Human Milk Oligosaccharides (HMO) Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, By Infant Formula, 2021-2031F |
6.2.3 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, By Functional Food & Beverages, 2021-2031F |
6.2.4 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, By Food Supplement, 2021-2031F |
6.3 Indonesia Human Milk Oligosaccharides (HMO) Market, By Concentration |
6.3.1 Overview and Analysis |
6.3.2 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, By Neutral, 2021-2031F |
6.3.3 Indonesia Human Milk Oligosaccharides (HMO) Market Revenues & Volume, By Acidic, 2021-2031F |
7 Indonesia Human Milk Oligosaccharides (HMO) Market Import-Export Trade Statistics |
7.1 Indonesia Human Milk Oligosaccharides (HMO) Market Export to Major Countries |
7.2 Indonesia Human Milk Oligosaccharides (HMO) Market Imports from Major Countries |
8 Indonesia Human Milk Oligosaccharides (HMO) Market Key Performance Indicators |
8.1 Research and development investment in HMO innovation and production techniques |
8.2 Consumer awareness and perception surveys on the benefits of HMOs in infant nutrition |
8.3 Number of partnerships and collaborations between HMO suppliers and infant formula manufacturers in Indonesia. |
9 Indonesia Human Milk Oligosaccharides (HMO) Market - Opportunity Assessment |
9.1 Indonesia Human Milk Oligosaccharides (HMO) Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Indonesia Human Milk Oligosaccharides (HMO) Market Opportunity Assessment, By Application, 2021 & 2031F |
9.3 Indonesia Human Milk Oligosaccharides (HMO) Market Opportunity Assessment, By Concentration, 2021 & 2031F |
10 Indonesia Human Milk Oligosaccharides (HMO) Market - Competitive Landscape |
10.1 Indonesia Human Milk Oligosaccharides (HMO) Market Revenue Share, By Companies, 2024 |
10.2 Indonesia Human Milk Oligosaccharides (HMO) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |